Ftse Mib
33.354,69
-0,95%
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
NASDAQ
17.689,36
-0,18%
Bitcoin
64.260,84
-0,86%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Outlook Therapeutics Inc (OTLK) Outlook Therapeutics Inc (OTLK) Notizie

OTLK

Outlook Therapeutics (OTLK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OTLK
DataOraFonteTitoloSimboloCompagnia
14/06/202422:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
11/06/202415:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceNASDAQ:OTLKOutlook Therapeutics Inc
28/05/202414:05GlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
15/05/202423:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
15/05/202423:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
15/05/202423:00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
13/05/202414:50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
09/05/202414:45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKOutlook Therapeutics Inc
07/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OTLKOutlook Therapeutics Inc
06/05/202422:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OTLKOutlook Therapeutics Inc
02/05/202415:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKOutlook Therapeutics Inc
29/04/202415:00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKOutlook Therapeutics Inc
15/04/202422:15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKOutlook Therapeutics Inc
22/03/202412:35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
18/03/202422:10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKOutlook Therapeutics Inc
12/03/202413:05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKOutlook Therapeutics Inc
11/03/202421:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
14/02/202414:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202413:00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202412:59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
31/01/202422:01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
31/01/202414:05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKOutlook Therapeutics Inc
24/01/202423:00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
23/01/202414:00GlobeNewswire Inc.Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010NASDAQ:OTLKOutlook Therapeutics Inc
22/12/202323:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OTLKOutlook Therapeutics Inc
22/12/202314:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUNASDAQ:OTLKOutlook Therapeutics Inc
19/12/202314:05GlobeNewswire Inc.Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NASDAQ:OTLKOutlook Therapeutics Inc
18/12/202311:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)NASDAQ:OTLKOutlook Therapeutics Inc
06/12/202314:05GlobeNewswire Inc.Outlook Therapeutics® Announces Strategic Organizational RealignmentNASDAQ:OTLKOutlook Therapeutics Inc
27/11/202314:05GlobeNewswire Inc.Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010NASDAQ:OTLKOutlook Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OTLK

La tua Cronologia

NYSE
SONX
Sonendo
USOTC
IMBBF
Imperial Brands (QX)
BIT
UC610S
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network